Synthesis and antiviral evaluation of cyclic and acyclic 2-methyl-3-hydroxy-4-pyridinone nucleoside derivatives

Journal of Medicinal Chemistry

Volumn 49, Issue 1, 2006, Pages 43-50

  Barral, Karine ^a   Balzarini, Jan ^b   Neyts, Johan ^b   De Clercq, Erik ^b   Hider, Robert C ^c   Camplo, Michel ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 HYDROXY 4 PYRIDINONE NUCLEOSIDE DERIVATIVE; DEFERIPRONE; IRON COMPLEX; NUCLEOSIDE DERIVATIVE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; IRON CHELATION; NONHUMAN; PKA;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL PROLIFERATION; CERCOPITHECUS AETHIOPS; HELA CELLS; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HIV-1; HIV-2; HUMANS; LIGANDS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; NUCLEOSIDES; PYRIDONES; STRUCTURE-ACTIVITY RELATIONSHIP; VERO CELLS;

EID: 30444437326     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0504306     Document Type: Article

References (35)

1. (a) Johnson, R. T. Emerging viral infections of the nervous system. J. Neurovirol. 2003, 9, 140-147.
2. (b) Wang, C. Y.; Sugden, B. New viruses shake old paradigms. J. Clin. Invest. 2004, 113, 21-23.
3. Arts, E. J.; Wainberg, M. A. Mechanisms of nucleoside analogue antiviral activity and resistance during Human Immunodeficiency Virus Reverse Transcription. Antimicrob. Agents Chemother. 1996, 40, 527-540.
4. (a) Lederman, H. M.; Cohen, A.; Lee, J. W. W.; Freedman, M. H.; Gelfand, E. W. Deferoxamine: a reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984, 64, 748-753.
5. (b) Van Asbeck, B. S.; Georgiou, N. A.; Van der Bruggen, T.; Oudshoorn, M.; Nottet, H. S. L. M.; Marx, J. J. M. Anti-HIV effect of iron chelators: different mechanisms involved. J. Clin. Virol. 2001, 20, 141-147.
6. Sappey, C.; Boelaert, J. R.; Legrand, P. S.; Forceille, C.; Favier, A.; Piette, J. Iron chelation decreases NF-kappa B and HIV type 1 activation due to oxidative stress. AIDS Res. Hum. Retroviruses 1995, 11, 1049-1061.
7. Georgiou, N. A.; van der Bruggen, T.; Hider RC.; Marx, J.; Van Asbeck, B. S. Human immunodeficiency virus type I replication inhibition by the bidentate iron chelators CP502 and CP511 is caused by proliferation inhibition and the onset of apoptosis. Eur. J. Clin. Invest. 2002, 52, 91-96.
8. (a) Tilbrook, G. S.; Hider, R. C. Iron chelators for clinical use. Metals Ions Biol. Syst. Sigel, A.; Sigel, H., Eds.; Iron Transport and Storage in Microorganisms, Plants and Animals, Marcel Dekker: New York, 1998; Vol. 35, pp 691-730.
9. 3+ Values. J. Med. Chem. 1999, 42, 4814-4823.
10. (c) Liu, Z. D.; Khodr, H.; Liu, D. Y.; Lu, S. L.; Hider R. C. Design, synthesis and evaluation of N-basic substituted 3-hydroxypyridin-4-ones: orally active iron chelators with lysosomotrophic potential. J. Pharm. Pharmacol. 2000, 52, 263-272.
11. (d) Liu, Z. D.; Hider R. C. Design of Clinically Useful Iron-(III)-Selective Chelators. Med. Res. Rev. 2002, 22, 26-64.
12. Hider, R. C.; Liu, Z. D.; Piyamongkol, S. The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe(3+) values. Transfus. Sci. 2000, 23, 201-209.
13. Georgiou, N. A.; van der Bruggen, T.; Oudshoorn, M.; Nottet, H.; Marx, J.; Van Asbeck, B. S. Human Combining iron chelators with the nucleoside analogue didanosine in anti-HIV therapy. Transfus. Sci. 2000, 23, 249-250 and ref 3b.
14. Liu, G.; Bruenger, F. W.; Miller, S. C.; Arif A. M. Molecular structure and biological and pharmacological properties of 3-hydroxy-2-methyl-1-(β-D- ribofuranosyl or pyranosyl)-4-pyridinone: potential iron overload drugs for oral administration. Bioorg. Med. Chem. Lett. 1998, 8, 3077-3080 and ref. herein.
15. (a) Tanaka, K.; Shionoya, M. Synthesis of a novel Nucleoside for Alternative DNA Base Pairing through Metal Complexation. J. Org. Chem. 1999, 64, 5002-5003.
16. (b) Tanaka, K.; Tengeiji, A.; Kato, T.; Toyama, N.; Shiro, M.; Shionoya, M. Efficient incorporation of a Copper-Hydroxypyridone Base Pair in DNA. J. Am. Chem. Soc. 2002, 124, 12494-12498.
17. (a)- Niedballa, U.; Vorbrüggen, H. Synthesis of nucleosides. 9. General synthesis of N-glycosides. I. Synthesis of pyrimidine nucleosides. J. Org. Chem. 1974, 39, 3654-3659.
18. (b)- Niedballa, U.; Vorbrüggen, H. Synthesis of nucleosides. II. General synthesis of N-glycosides. J. Org. Chem. 1974, 39, 3664-3667.
19. (c)- Vorbrüggen, H.; Hoetle, G. Nucleoside syntheses. XXIII. On the mechanism of nucleoside synthesis. Chem. Ber. 1981, 114, 1256-1268.
20. (a) Liu, G.; Bruenger, F. W.; Barrios, A. M.; Miller, S. C. Synthesis of 2-alkyl-3-hydroxy-4-pyridinone-ribonucleosides, potential oral iron chelators. Nucleosides Nucleotides. 1995, 14, 1901-1904.
21. (b) Mao, D. T.; Driscoll, J. S.; Marquez, V. E. Synthesis of 3-Hydroxy-2- and -4-pyridone Nucleosides as Potential Antitumor Agents. J. Med. Chem. 1984, 27, 160-164.
22. Choi, W. B.; Wilson, L. J.; Yeola, S.; Liotta, D. C. In situ Complexation Directs the Stereochemistry of N-Glycosylation in the Synthesis of Oxathiolanyl and Dioxalanyl Nucleoside Analogues. J. Am. Chem. Soc. 1991, 113, 9377-9379.
23. (a) Jung, M. E.; Lyster, M. A. Quantitative Dealkylation of Alkyl Ethers via Treatment with Trimethylsilyl Iodide. A New Method for Ether Hydrolysis. J. Org. Chem. 1977, 42, 3761-3764.
24. (b) Huang, J. J.; Rideout, J. L.; Martin, G. E. Synthesis of (±)-cis-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine and its (±)-trans isomer. Nucleosides Nucleotides 1995, 14, 195-207.
25. (a) Jeffery, A. L.; Kim, J.-H.; Wiemer, D. F. Synthesis of Acyclic Nucleoside and Nucleotide Analogues from Amino Acids: A Convenient Approach to a PMEA-PMPA Hybrid. Tetrahedron. 2000, 56, 5077-5083.
26. (b) Brodfuehrer, P. R.; Howell, H. G.; Sapino, C.; Vemishetti P. A Practical Synthesis of (S)-HPMPC. Tetrahedron Lett. 1994, 35, 3243-3246.
27. (c) Matulic-Adamic, J.; Haeberli, P.; Usman, N. Synthesis of 5′-Deoxy-5′-difluoromethyl Phosphonate Nucleotide Analogues. J. Org. Chem. 1995, 60, 2563-2569.
28. (d) Wormstädt, F.; Brinckmann, U.; Gütschow, M.; Eger, K. Synthesis of Acyclic Nucleoside Phosphonates as Antiviral Compounds. J. Heterocycl. Chem. 2000, 37, 1187-1191.
29. Liu, Z.-D.; Hider, R. C. Design of clinically useful iron(III)-selective chelators. Med. Res. Rev. 2002, 22(1), 26-64.
30. Mourier, N.; Camplo, M.; Schioppacassi, G.; Pellacini, F.; Ungheri, D.; Chermann, J. C.; Kraus, J. L. Synthesis and anti-HIV evaluation of new 2′,3′-dideoxy-3′-thiacyctidine prodrugs. Nucleosides, Nucleotides Nucleic Acids 2000, 19(7), 1057-1091.
31. Dobbin, P. S.; Hider, R. C.; Hall, A. D.; Taylor, P. D.; Sarpong, P.; Porter, J. B.; Xiao, G.; van der Helm, D. Synthesis, Physicochemical Properties, and Biological Evaluation of N-Substituted 2-Alkyl-3-hydroxy-4(1H)-pyridinones: Orally Active Iron Chelators with Clinical Potential. J. Med. Chem. 1993, 36, 2448-2458.
32. Agyei-Aye, K. and Baker, D. C. Synthesis and evaluation of a series of 1-(3-alkyl-2,3-dideoxy-α,β-D-erythro-pentofuranosyl)thymines. Carbohyd. Res. 1998, 183, 261-275.
33. De Clercq, E.; Descamps, J.; Verhelst, G.; Walker, R. T.; Jones, A. S.; Torrence, P. F.; Shugar, D. Comparative efficacy of different antiherpes drugs against different strains of herpes simplex virus. J. Infect. Dis. 1980, 141, 563-574.
34. Snoeck, R., G. Andrei, E. De Clercq, M. Gerard, N. Clumeck, G. Tricot, Sadzot-Delvaux, C. A new topical treatment for resistant herpes simplex infections. N. Engl. J. Med. 1993, 329, 968-969.
35. Balzarini, J.; Hatse, S.; Vermeire, K.; Princen, K.; Aquaro, S.; Perno, C.-F.; De Clercq, E.; Egberink, H.; Vanden Mooter, G.; Peumans, W.; Vandamme, E.; Schols, D. Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. Antimicrob. Agents Chemother. 2004, 48, 3858-3870.